Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00002202 · ClinicalTrials.gov registry record · Phase 3
A Comparison of 141W94 and Indinavir in HIV-Infected Patients
A Phase 3 study, sponsored by Glaxo Wellcome.
- Completed
- Registry status
- Phase 3
- Development phase
- 460
- Enrollment target
NCT00002202 is a Phase 3 study that has completed, run by Glaxo Wellcome. The registered enrollment target is 460 participants.
The verdict
NCT00002202, a Phase 3 study, has completed, sponsored by Glaxo Wellcome.
- COMPLETED
- Registry status
- Phase 3
- Development phase
- 460 participants
- Enrollment target
Study Summary
The purpose of this study is to see if 141W94 is as safe and effective as indinavir when used with nucleoside reverse transcriptase inhibitors (NRTIs) for 48 weeks. This study also examines what effect other drugs have on how the body handles 141W94.
Interventions
- DRUG Indinavir sulfate
- DRUG Amprenavir
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 460 participants |
| Phase | Phase 3 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00002202
The ClinicalTrials.gov registry entry for NCT00002202 describes a study currently listed as completed, categorized as Phase 3. The registered enrollment target is 460 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Glaxo Wellcome, which has 65 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which Indinavir sulfate is the first listed.
NCT00002202 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00002202 about?
NCT00002202 is a clinical study titled "A Comparison of 141W94 and Indinavir in HIV-Infected Patients". The purpose of this study is to see if 141W94 is as safe and effective as indinavir when used with nucleoside reverse transcriptase inhibitors (NRTIs) for 48 weeks. This study also examines what effect other drugs have on how the body handles 141W94.
What is the current status of trial NCT00002202?
This trial is currently completed. It is a Phase 3 study. The enrollment target is 460 participants.
What interventions are being tested in trial NCT00002202?
The interventions under investigation include: Indinavir sulfate (DRUG), Amprenavir (DRUG).
Who is sponsoring clinical trial NCT00002202?
This trial is sponsored by Glaxo Wellcome, which has 65 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.